This clinical trial is focused on studying the effectiveness and safety of a new treatment for pain associated with diabetic peripheral neuropathy. Diabetic peripheral neuropathy is a condition that affects the nerves in the lower extremities, often causing pain. The study will test a medication called VX-993, which is a tablet designed to help manage this type of pain. VX-993 works by inhibiting a specific sodium channel in the body, which is thought to play a role in pain sensation. Another medication, pregabalin, which is commonly used to treat nerve pain, will also be used in the study for comparison. Some participants will receive a placebo, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate how well different doses of VX-993 can reduce pain in people with diabetic peripheral neuropathy and to assess its safety. Participants will take the medication orally, and the study will last for up to 12 weeks. During this time, participants will be monitored for any changes in their pain levels and any side effects they might experience. The study will also compare the effects of VX-993 with those of pregabalin to see which is more effective in managing pain.

Throughout the study, participants will have regular check-ins to track their progress and ensure their safety. The main goal is to see if VX-993 can significantly reduce pain compared to the placebo and pregabalin. The study will also look at how well participants tolerate the medication, considering any adverse effects, changes in laboratory test results, and vital signs. This research aims to provide a better understanding of how VX-993 can be used to help people with diabetic peripheral neuropathy manage their pain more effectively.